Biomaterials Asia 2009 Conference Highlights Leading Biomaterials Science in Asia

Oxford, 26 March 2009 – Elsevier announced today, that Biomaterials, the leading journal in the field of biomaterials science, will host Biomaterials Asia 2009 in Hong Kong from April 5-8 to highlight the latest Asian research developments, institutions, and individuals in biomaterials science.

Under the chairmanship of Professor David Williams, Editor-in-Chief of Biomaterials, the conference program will focus on the interface between advanced materials science and biological science, bringing the latest expertise in advanced medical engineering, clinical sciences and regenerative medicine under one roof.

This event, with keynote speakers drawn from the world’s best scientists, will provide an unparalleled opportunity for researchers, technologists and clinicians in the fields of bioengineering, medical device technology, pharmaceutical science, tissue engineering and biomaterials science to explore and debate the latest scientific developments, translational science and commercial applications. Conference sessions will be modeled after the scientific sections defined by Biomaterials, the world’s foremost journal in the field with an Impact Factor of 6.262.

“Biomaterials science is concerned with the reconstruction of the human body through the use of implantable medical devices and the technologies of regenerative medicine,” remarked Professor Williams, conference Chair and Editor-in-Chief of Biomaterials, “Biomaterials Asia 2009 will enable some of the best laboratories and hospitals across Asia to showcase many of the topical technologies that are responsible for significant advances in health care, including stem cell science, nanomedicine and tissue engineering.”

“Research laboratories and hospitals across Asia are making such a tremendous contribution to the latest developments in biomaterials, that we are delighted to set a precedent with this unique forum,” added YS Chi, Vice Chairman at Elsevier, who will officially open the conference on April 5th, “Biomaterials Asia enables us to honor world class scientists and clinicians across Asia who are making critical contributions to global health care.”

# # #

Notes to Editors:
Seeram Ramakrishnam, Vice President, National University of Singapore and Tim Pratt, Executive VP and General Counsel, Boston Scientific will also be at the opening ceremony, alongside Professor Williams and YS Chi.
Highlights of the program include Rocky Tuan (NIH, USA) who will be talking about adult stem cells and nanomaterials in skeletal tissue engineering and regenerative medicine; and Si-Shen Feng from the National University of Singapore, discussing nanoparticles of biodegradable polymers for diagnosis and treatment of cancer.
For more information please see the
 full program online.

About Biomaterials 
Biomaterials
 is the leading international journal covering the science and application of biomaterials and associated medical devices. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review papers dealing with the most important issues facing the use of materials in clinical practice. The journal is relevant to all applications of biomaterials including implantable medical devices, tissue engineering and drug delivery systems.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Name Deborah Logan
Phone +44(0)1865 843061
E-mail d.logan@elsevier.com